secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2023-01-26T23:59:59+00:00
Accession:  0001564590-23-000832
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology receives FDA IND clearance for SC291 allogeneic CAR T therapy in B-cell malignancies
--------------------------------------------------------------------------------

- FDA cleared IND for SC291, a CD19-targeted allogeneic CAR T therapy using Sana's hypoimmune platform, in patients with B-cell lymphomas or leukemias.
- Goal to report initial SC291 clinical data in 2023; second IND for SC262 (CD22-targeted) expected this year.
- Hypoimmune platform disrupts MHC class I/II expression and overexpresses CD47 to evade immune rejection.
- Preclinical data shown across models; platform also being developed for pancreatic islet cell therapy in type 1 diabetes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000156459023000832/0001564590-23-000832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000156459023000832/sana-8k_20230126.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-000832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer